Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Holding ANIP?
Track your performance easily
ANIP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$48.20 - $70.81
Previous Close$55.69
Volume365.20K
Average Volume (3M)314.23K
Market Cap
$1.17B
Enterprise Value$1.22B
Total Cash (Recent Filing)$240.11M
Total Debt (Recent Filing)$285.24M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Feb 27, 2025EPS Estimate
$1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding21,030,069
10 Day Avg. Volume316,412
30 Day Avg. Volume314,229
Standard Deviation0.12
R-Squared0.10
Alpha-0.00683
Financial Highlights & Ratios
Price to Book (P/B)2.54
Price to Sales (P/S)2.17
Price to Cash Flow (P/CF)16.80
P/FCF Ratio15.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.30
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda36.00
Forecast
1Y Price Target
$76.75Price Target Upside39.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ANI Pharmaceuticals News
PremiumCompany Announcements
ANI Pharmaceuticals Advances Amidst Regulatory and Market Challenges
PremiumCompany Announcements
ANI Pharmaceuticals’ Record Growth and Strategic Acquisition
Bulls Say, Bears Say
Bulls Say
Business StrategyThe recent addition of Iluvien and Yutiq via the Alimera acquisition strengthens ANI’s rare disease brand portfolio, which is expected to account for 45%+ of the top-line in 2025.
Financial PerformanceANI continues its streak of execution vs. conservative guidance, beating revenue estimates for the 10th straight quarter, and raising guidance again for Cortrophin Gel and generics/other business outperformance.
Market PositionAnalyst reiterates Buy rating and highlights a Street-high $94 price target, suggesting the stock is easy to own and deserving of premium multiples.
Bears Say
Acquisition RisksClosure delays of Alimera acquisition imply potential post due diligence issues, likely on manufacturing deficiencies of Yutiq.
Legal And Contractual ChallengesAlimera announced it has taken legal action against ANI for failure to fulfill its contractual obligation to close the transaction.
Regulatory IssuesAn unwelcome surprise related to this Alimera acquisition is an FDA Warning Letter issued to Alimera’s 3rd-party manufacturer of Iluvien and Yutiq.
---
Ownership Overview
10.13% Insiders
18.15% Mutual Funds
23.68% Other Institutional Investors
25.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANIP FAQ
What was ANI Pharmaceuticals Inc’s price range in the past 12 months?
ANI Pharmaceuticals Inc lowest stock price was $48.20 and its highest was $70.81 in the past 12 months.
What is ANI Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is ANI Pharmaceuticals Inc’s upcoming earnings report date?
ANI Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 98 days.
How were ANI Pharmaceuticals Inc’s earnings last quarter?
ANI Pharmaceuticals Inc released its earnings results on Nov 08, 2024. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.086 by $0.254.
Is ANI Pharmaceuticals Inc overvalued?
According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued.
Does ANI Pharmaceuticals Inc pay dividends?
ANI Pharmaceuticals Inc does not currently pay dividends.
What is ANI Pharmaceuticals Inc’s EPS estimate?
ANI Pharmaceuticals Inc’s EPS estimate is $1.45.
How many shares outstanding does ANI Pharmaceuticals Inc have?
ANI Pharmaceuticals Inc has 21,017,775 shares outstanding.
What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?
ANI Pharmaceuticals Inc reported an EPS of $1.34 in its last earnings report, beating expectations of $1.086. Following the earnings report the stock price went up 5.242%.
Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?
Among the largest hedge funds holding ANI Pharmaceuticals Inc’s share is Maverick Capital ltd. It holds ANI Pharmaceuticals Inc’s shares valued at 1M.
---
ANI Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.75 (39.29% Upside)
$76.75 (39.29% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $375.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 15.8%
Last 30 Days ▼ 15.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.36%
12-Months-Change
Fundamentals
Return on Equity
-2.13%
Trailing 12-Months
Asset Growth
44.66%
Trailing 12-Months
Company Description
ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
---
ANIP Earnings Call
Q3 2024
0:00 / 0:00
---
ANIP Stock 12 Month Forecast
Average Price Target
$76.75
▲(39.29% Upside)
Technical Analysis
Best Analysts Covering ANIP
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+16.37%
reiterated a buy rating 9 months ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +16.37% per trade.
---